Полный текст:


Тиотропия бромид для терапии хронической обструктивной болезни легких: слагаемые успеха

Об авторе

С. Н. Авдеев
ФГУ "НИИ пульмонологии" ФМБА России

д. м. н., проф., руководитель клинического отдела 

105077, Москва, ул. 116я Парковая, 32, к. 4.

Тел: (495) 465-53-64.

Список литературы

1. Global Initiative for Chronic Obstructive Lung Diseas(GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease.NHLBI / WHO workshop report. The 2009 report is available on www.goldcopd.com

2. Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet 2007; 370:741–750.

3. Чучалин А.Г., Овчаренко С.И., Лещенко И.В., Белевский А.С. Определение, классификация и диагностика ХОБЛ. В кн.: Чучалин А.Г. (ред.). Клинические рекомендации. Хроническая обструктивная болезнь легких. М.: Атмосфера, 2007. 8–22.

4. Celli B.R., MacNee W., ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS / ERS position paper. Eur. Respir. J.2004; 23: 932–946.

5. Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–189.

6. Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr.Opin. Pulm. Med. 2010; 16: 97–105.

7. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month,placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.

8. Celli B., Wallack R.Z., Wang S. et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748.

9. Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34: 757–769.

10. Bauwens O., Ninane V., Van de Maele B. et al. 24-hour bronchodilator efficacy of single doses indacaterol in subjects with COPD: comparison with placebo and formoterol.Curr. Med. Res. Opin. 2009; 25: 463–470.

11. Beier J., Beeh K.M., Brookman L. et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Ther. 2009; 22 (6): 492–496.

12. Fogarty C., Worth H., Hebert J. et al. Sustained 24-h bronchodilation with indacaterol once-daily in COPD: a 26-week efficacy and safety study. Am. J. Respir. Crit. Care Med.2009; 179: A4547.

13. Magnussen H., Paggiaro P., Jack D. et al. Bronchodilatador treatment with indacaterol once daily vs formoterol twicedaily in COPD: a 52 week study. Am. J. Respir. Crit. Care Med. 2009; 179: A6184.

14. Nonikov V., Verkindre C., Jack D. et al. Indacaterol once-daily reduces days of poor control in COPD over 52 weeks of treatment. Am. J. Respir. Crit. Care Med. 2009; 179: A6190.

15. Magnussen H., Paggiaro P., Jack D. et al. Indacaterol once-daily improves health related quality of life in COPD patients: a 52-week study versus placebo and formoterol.Eur. Respir. J. 2009; 53s: P2019.

16. Buhl R., Pieters W., Jack D. et al. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study versus twice daily formoterol. Eur. Respir.J. 2009; 53s: P2026.

17. Buhl R., Pieters W., Jack D. et al. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment.Am. J. Respir. Crit. Care Med. 2009; 179: A6185.

18. Worth H., Kleerup E., Iqbal A. et al. Safety and tolerability of indacaterol once daily in COPD patients versus placebo and tiotropium: a 26 week study. Eur. Respir. J. 2009; 53s:P2030.

19. Chung F., Kornmann O., Jack D. et al. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur.Respir. J. 2009; 53s: E4359.

20. Fletcher C.M., Elmes P.C., Wood C.H. The significance of respiratory symptoms and the diagnosis of chromic bronchitis in a working population. Br. Med. J. 1959; 1: 257–266.

21. Kohansal R., Martinez%Camblor P., Agusti A. et al. The natural history of chronic airflow obstruction revisited: an analysis of the framingham offspring cohort. Am. J. Respir. Crit.Care Med. 2009; 180: 3–10.

22. Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the Uplift trial. COPD 2004; 1: 303–312.

23. Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study.Am. J. Respir. Crit. Care Med. 2000; 161: 381–390.

24. Anthonisen N.R., Skeans M.A.,Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142:233–239.

25. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl.J. Med. 2008; 359: 1543–1554.

26. Vincken W., van Noord J.A., Greefhorst A.P.M. et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19:209–216.

27. Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther.2005; 18: 75–81.

28. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948–1953.

29. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.Lancet 1999; 353: 1819–1823.

30. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med.2000; 343: 1902–1909.

31. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000;320: 1297–1303.

32. Decramer M., Rutten%van Molken M., Dekhuijzen P.N. et al.Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552–1560.

33. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of COPD: a randomized controlled trial. Lancet 2003; 361 (9356): 449–456.

34. Decramer M., Celli B., Kesten S. et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374:1171–1178.

35. Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65–73.

36. Morice A.H., Celli B., Kesten S. et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659–1667.

37. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.

38. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States,1971–2000. Morbid. Mortal. Wkly Rep. Surveill. Summ.2002; 51: 1–16.

39. World Health Organization. Global initiative for chronic obstructive lung disease. Geneva (Switzerland): World Health Organization; 2002.

40. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.

41. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93:391–398.

42. Anthonisen N.R., Skeans M.A.,Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142:233–239.

43. National Emphysema Treatment Trial Research Group.A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl.J. Med. 2003; 348: 2059–2073.

44. Lightowler J.V., Wedzicha J.A., Elliott M.W., Ram F.S.Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Br. Med. J. 2003; 326: 185–189.

45. Salpeter S.R., Buckley N.S., Salpeter E.E. Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J. Gen. Intern.Med. 2006; 21: 1011–1019.

46. De Luise C., Lanes S.F., Jacobsen J. et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur. J. Epidemiol. 2007; 22:267–272.

47. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809–814.

48. Camilli A.E., Robbins D.R., Lebowitz M.D. Death certificate reporting of confirmed airways obstructive disease. Am. J.Epidemiol. 1991; 133: 795–800.

49. Engstrom G., Wollmer P., Hedblad B. et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914",Malmo, Sweden. Circulation 2001; 103: 3086–3091.

50. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 26400–2646.

51. Viegas C.A., Ferrer A., Montserrat J.M. Ventilation-perfusionresponse after fenoterol in hypoxemic patients with stable COPD. Chest 1996; 110: 71–77.

52. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. J.A.M.A. 2008; 300: 1439–1450.

53. Celli B., Decramer M., Leimer I. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137;20–30.

54. Reilly J.J. COPD and declining FEV1 – time to divide and conquer? N. Engl. J. Med. 2008; 359: 1616–1618.

55. Burrows B., Fletcher C.M., Heard B.E. et al. The emphysematous and bronchial types of chronic airways obstruction.A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830–835.

56. Garcia-Aymerich J., Agusti А., Barberа J.A. et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease.Arch. Bronconeumol. 2009; 45: 133–142.

57. Han M.K., Agusti A., Calverley P.M. et al. COPD phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med.2010; 182: 598–604.

58. Lee J.-H., Lee Y.K., Kim E.-K. et al. Responses to inhaled Long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010; 104: 542–549.

59. Gelb A.F., Taylor C.F., Cassino C. et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD.Pulm. Pharmacol. Ther. 2009; 22: 237–242.

60. Tashkin D.P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. 2010; 35: 287–294.

61. Tashkin D.P., Celli B., Kesten S. et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir. Med. 2010; 104: 1495–1504.

Дополнительные файлы

Для цитирования: Авдеев С.Н. ТИОТРОПИЯ БРОМИД ДЛЯ ТЕРАПИИ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ: СЛАГАЕМЫЕ УСПЕХА.  Пульмонология. 2011;(1):100-106. https://doi.org/10.18093/0869-0189-2011-0-1-100-106

For citation: Avdeev S.N. TIOTROPIUM BROMIDE IN THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RECIPE FOR SUCCESS. Russian Pulmonology. 2011;(1):100-106. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-1-100-106

Просмотров: 222

Обратные ссылки

  • Обратные ссылки не определены.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)